Azenta (AZTA) Stock News

Fresenius Medical Care (NYSE:FMS) announced a strategic collaboration between its research organization Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences to advance genomic analysis of kidney disease through the My Reason® genomics program.

The collaboration leverages Frenova's registry of over 35,000 participants (targeting 50,000 in two years) to create the world's largest cardio-kidney-metabolic disease database. GENEWIZ will provide DNA sequencing and biospecimen storage, while Nephronomics holds exclusive commercial rights to develop targeted therapies using AI/ML models.

This initiative aims to transform kidney care through personalized medicine by analyzing genetic mechanisms underlying kidney, cardiovascular, and metabolic diseases.

Azenta (Nasdaq: AZTA) announced its participation in the upcoming 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The company's management team will attend the virtual event scheduled for Tuesday, August 12, 2025. This conference provides an opportunity for investors and analysts to engage with Azenta's leadership through one-on-one meetings.

Azenta (Nasdaq: AZTA) has scheduled its fiscal third quarter 2025 earnings announcement for Tuesday, August 5, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results for the quarter ended June 30, 2025.

Stakeholders can access the live webcast through the company's investor relations website. A replay of the event will become available starting at 8:30 a.m. ET on August 6, 2025.

Azenta's GENEWIZ division has formed a strategic partnership with Form Bio to enhance adeno-associated virus (AAV) gene therapy development. The collaboration integrates GENEWIZ's next-generation sequencing services with Form Bio's AI-powered analysis pipelines to improve AAV gene therapy development workflows.

The partnership combines GENEWIZ's capabilities in synthesis, packaging of transgene expression cassettes, and long-read sequencing services with Form Bio's comprehensive AAV Genome Integrity Characterization using LAAVA software. This integration aims to streamline processes, reduce development time and costs, and provide better insights into AAV capsid contents for improved safety, efficacy, and manufacturability.

The partnership will be officially launched at the 27th Annual ASGCT Meeting in May 2025, where both companies will present their collaborative research.

Azenta (NASDAQ: AZTA) reported its Q2 FY2025 financial results with revenue of $143 million, showing a 5% year-over-year increase and 6% organic growth. The company's Sample Management Solutions revenue grew 8% to $80 million, while Multiomics revenue increased 2% to $64 million. Despite revenue growth, Azenta reported a GAAP operating loss of $16 million with operating margin at -11.3%. The company maintained strong liquidity with $540 million in cash and equivalents. Adjusted EBITDA was $14 million with a 10% margin, showing a 400 basis point improvement year-over-year. Management reiterated its FY2025 guidance, expecting organic revenue growth of 3-5% and adjusted EBITDA margin expansion of approximately 300 basis points.

Azenta (Nasdaq: AZTA) has scheduled its fiscal 2025 second quarter earnings announcement for Wednesday, May 7, 2025, before market opening. The earnings report will cover the quarter ended March 31, 2025.

The company will host a conference call and live webcast to discuss the financial results on May 7, 2025, at 8:30 a.m. Eastern Time. Investors, analysts, and media representatives can access the live webcast through Azenta's investor relations website. A replay of the event will be available starting May 8, 2025, at 8:30 a.m. ET.

Azenta (Nasdaq: AZTA) has released its 2024 Environmental, Social, & Governance (ESG) Report, outlining achievements across three main pillars: Environmental Protection, Social Impact, and Responsible Operations.

Key 2024 milestones include:

• ~20% reduction in Scope 1 & 2 Greenhouse Gas emissions compared to 2022
• Over 60% electricity sourced from renewable sources
• Launch of BioArc™ Ultra for eco-friendly sample storage
• Introduction of LGBTQIA+ Employee Resource Group (Azenta PRISM)
• Implementation of Azenta THRIVE platform with LinkedIn Learning® integration
• 100% of global buyer team trained on sustainable sourcing
• EcoVadis® partnership expansion to evaluate ESG performance of over 50% of Tier 1 suppliers by spend

Azenta (Nasdaq: AZTA) has announced its participation in the upcoming Virtual KeyBanc Capital Markets Healthcare Forum. The company's Executive Vice President and Chief Financial Officer, Lawrence Y. Lin, will deliver a presentation at the event on Wednesday, March 19, 2025, at 10:30 am ET.

Investors and interested parties can access the live webcast through the Azenta investor relations website at https://investors.azenta.com/events. A replay option will be made available after the presentation concludes.

Azenta (NASDAQ: AZTA) reported Q1 FY2025 results with revenue from continuing operations at $148 million, up 4% year-over-year. The company's performance was marked by growth in both major segments: Sample Management Solutions revenue reached $81 million (+3% YoY) and Multiomics revenue hit $66 million (+6% YoY).

The company reported a diluted EPS loss of ($0.21) from continuing operations and total diluted EPS of ($0.29). Adjusted EBITDA was $13 million with a margin of 9.0%, showing a 400 basis point improvement year-over-year. The quarter ended with $530 million in cash, cash equivalents, and marketable securities, generating free cash flow of $22 million.

For FY2025, Azenta maintains its guidance of 3-5% organic revenue growth and expects adjusted EBITDA margin expansion of approximately 300 basis points compared to FY2024.